This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Catalog Advanced Search
20 items were found using the following search criteria
-
Lyonbiopôle: The Challenge of Becoming a World-class Biotechnology Cluster
Anthony Goerzen; Ana ColovicCase IVEY-9B09M075-EStrategyIn December 2007, the Economics & International Affairs director of the competitiveness cluster, Lyonbiopôle, was responsible for the international development of the cluster. Lyonbiopôle was one of seven biotechnology clusters in France. Although Lyonbiopôle performed very well at the national level, its visibility as an international cluster in the biotechnology field was uncertain. Yet, for its member firms to thrive in the globalized world of...Starting at €8.20
-
Professionalization of Ujwal Bharati
Kavil RamachandranCase IVEY-9B10M036-EEntrepreneurship, StrategyThe case considers the dilemma faced by the second generation managing director of Ujwal Bharati Pharmaceuticals, a mid-size business in India. Among other issues related to corporate and family governance, he has to decide whether to retain his non-family CEO or not.This case was written in the context of the major efforts made by mid-size Indian family businesses in recent years to professionalize their operations. While the director appreciate...Starting at €8.20
-
Immunovaccine (IMV): Preparing to Cross the Valley of Death
Ella Korets-Smith; Suhaib RiazCase IVEY-9B10M072-EEntrepreneurship, Leadership and People Management, StrategyThe case describes the challenges faced by Immunovaccine (IMV), a small biotechnology company founded in Halifax, Canada. The company has seen early success in the effectiveness of its technology in animal health and is looking for ways to exploit the potential of its technology more broadly, particularly in human health. The company's challenges are presented in the context of the evolving relationship between the pharmaceutical and biotechnolog...Starting at €8.20
-
Dr. Amita Joshi at Samuel Drugs Limited
Anup K. Singh; Abhinav GuptaCase IVEY-9B11C006-ELeadership and People Management, StrategyAWARD-WINNING CASE: Adjudged second-best case at the ISB Case Competition 2010 held in partnership with the Richard Ivey School of Business and the Association of Indian Management Schools and sponsored by the Chartered Institute of Management Accountants.This case describes the successful journey of Dr. Amita Joshi in a medium-sized Indian pharmaceuticals organization, Samuel Drugs, which was facing serious performance problems. As CEO, Joshi re...Starting at €8.20
-
Birzeit Pharmaceutical Company: Marketing from Palestine
Yara Asad; Ilan AlonCase IVEY-9B10A027-EEntrepreneurship, Marketing, StrategyBirzeit Pharmaceutical Company (BPC), established in 1974, had successfully completed a number of mergers and had overcome challenges and development phases in order to secure a strong position in its local market, Palestine, as well as introduce a wide range of products in the export market. BPC’s continuous success, despite political instability and continuous restrictions on its growth and expansion, led the company to focus beyond its local p...Starting at €8.20
-
The Generics Pharmacy
Jim KayalarCase IVEY-9B11M022-EEntrepreneurship, StrategyThe price of pharmaceuticals in the Philippines is second only to Japan within Asia and is among the highest in the world, despite the Philippines being a less developed country with nearly half of its population living on US$2 a day. The case illustrates how The Generics Pharmacy, a local pharmaceutical company, challenged the existing industry business model and became the largest pharmaceutical retailer in the country within a period of only t...Starting at €8.20
-
AstraZeneca: Transforming How New Medicines Flow to Patients
Snell, Scott A.; Yemen, GerryCase DARDEN-S-0221-EStrategyThis case is currently taught in Darden's ""First-Year Strategy"" course. Scott Snell also teaches it in his second year elective, ""Developing Organizational Capability"". The case would be useful in any course that examines the topic of core capabilities, organizational change, or strategic alignment. This field-based case provides an overview of reorganization at AstraZeneca UK Limited (AZN) and focuses on the processes, systems, and people (h...Starting at €8.20
-
Parkin Laboratories: Sales Target Dilemma
Sandeep PuriCase IVEY-9B13A017-EMarketing, StrategyAt the end of the year’s third quarter, the sales team at a generic-pharmaceutical company has achieved just 91 per cent of its sales target, and growth is less than what was anticipated. The general manager of sales needs to decide whether he can revise the sales targets for the last quarter of the year without compromising growth. He also needs to address the impact of launching a new product when the sales team is striving to achieve its budge...Starting at €8.20
-
Novartis’ Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries’ Health Care Systems
Chess, R; Luthre, JCase SGSB-E489-EEntrepreneurshipInternational healthcare and reimbursement systems underwent a radical transformation in the 2000s, resulting from growing financial pressures incited by economic depression and a steady rise in healthcare spending. This phenomenon was most pronounced in the United States, where the health-spending share of GDP rose from five percent in 1960 to 17.9 percent in 2011. In Organization for Economic Co-operation and Development (OECD) countries on a...Starting at €8.20
-
Novartis’ Gilenya: Navigating the Interplay Between Drug Innovation, Pricing, and Reimbursement in Different Countries’ Health Care Systems - Teaching Note
Chess, R; Luthre, JTeaching Note SGSB-E489TN-EEntrepreneurshipInternational healthcare and reimbursement systems underwent a radical transformation in the 2000s, resulting from growing financial pressures incited by economic depression and a steady rise in healthcare spending. This phenomenon was most pronounced in the United States, where the health-spending share of GDP rose from five percent in 1960 to 17.9 percent in 2011. In Organization for Economic Co-operation and Development (OECD) countries on a...Starting at €0.00